 "Ranbaxy shares grow by 6% as Q4 net loss narrows")
The company's stock ended at Rs 340.05, up 5.69% on the BSE. During the day, the scrip surged 7.84% to Rs 347. Ranbaxy's shares settled 5.75% higher at Rs 340.45 on NSE.
"Ranbaxy Lab posted results better-than-expected, on the operational front," said Sarabjit Kour Nangra, VP Research Pharma, Angel Broking. Ranbaxy Laboratories's fourth-quarter net loss narrowed to Rs 158.94 crore, mainly on account of higher sales of its Absorica acne drug.
Also Read
The company had posted a loss of Rs 492.44 crore a year earlier, according to a statement.
"Ranbaxy has been strengthening its base business in key markets, including India, Eastern Europe and the USA, which has helped us recover our margins," Arun Sawhney, Chief Executive Officer and Managing Director, said in a statement.
Ranbaxy also said it made a provision of Rs 257.4 crore towards the financial impact of a US ban on import of products made at its plant at Toansa.
Revenue rose 6.7% to Rs 2,894 crore in the quarter from Rs 2,711.2 crore in the year-ago period. North America sales were Rs 1,020 crore, Ranbaxy said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%